Reaction

Embolism Venous reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,996 reports · 113 co-occurring drugs

As of the last recalculation, Embolism Venous appears in 2,996 FAERS reports alongside 113 co-occurring drug terms. The strongest observed disproportionality signal is ETONOGESTREL AND ETHINYL ESTRADIOL (PRR 38.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Etonogestrel And Ethinyl Estradiol	118	38.4	38.6
Haloperidol Lactate	102	29.6	29.7
Haloperidol	88	25.9	26.0
Psyllium Husk	34	24.2	24.3
Raloxifene Hydrochloride	49	23.7	23.8
Abemaciclib	44	15.5	15.5
Nystatin Ointment	53	14.3	14.3
Nystatin Cream	53	14.3	14.3
Tranexamic Acid	18	14.1	14.2
Nystatin	53	13.7	13.7
Testosterone Cypionate	17	13.3	13.3
Docusate Sodium - Sennosides	59	12.9	13.0
Pemetrexed	38	12.5	12.5
Drospirenone And Ethinyl Estradiol	76	12.2	12.3
Bevacizumab	196	11.7	11.7
Irinotecan Hydrochloride	21	11.4	11.4
Risedronate Sodium	50	11.3	11.4
Baricitinib	15	10.9	10.9
Fluticasone Furoate And Vilanterol Trifenatate	51	10.0	10.0
Clarithromycin	48	9.9	9.9
Thalidomide	51	9.8	9.8
Fluticasone Propionate Nasal	41	9.5	9.5
Estradiol Gel 0.1%	60	9.4	9.4
Estradiol Transdermal	60	9.4	9.4
Pegaspargase	15	8.5	8.6
Pemetrexed Disodium	46	8.5	8.5
Docusate Sodium	68	8.3	8.4
Upadacitinib	94	8.2	8.2
Rivaroxaban	229	8.2	8.2
Carfilzomib	33	8.2	8.2
Melphalan Hydrochloride	29	8.1	8.1
Fluticasone Furoate	14	8.1	8.1
Mercaptopurine	19	7.7	7.7
Eplerenone	14	7.6	7.6
Cisplatin	83	7.6	7.6
Dexamethasone Sodium Phosphate	11	7.5	7.6
Romiplostim	16	7.4	7.4
Testosterone	24	7.2	7.2
Heparin Sodium	14	7.1	7.1
Gemcitabine	39	7.0	7.0
Fluconazole	68	6.9	6.9
Melphalan	22	6.8	6.8
Risperidone	122	6.6	6.6
Moxifloxacin Hydrochloride	19	6.5	6.6
Oxaliplatin	68	6.5	6.5
Tofacitinib Citrate	12	6.4	6.4
Gemcitabine Hydrochloride	48	6.4	6.4
Apixaban	60	6.3	6.3
Carboplatin	107	6.0	6.0
Paclitaxel (Aibumin-Bound)	69	5.9	5.9
Moxifloxacin	12	5.9	5.9
Dalteparin Sodium	9	5.9	5.9
Olanzapine	88	5.8	5.8
Estradiol	69	5.7	5.7
Temozolomide	17	5.6	5.6
Fluorouracil Cream, 0.5%	59	5.5	5.5
Fluorouracil	59	5.4	5.4
Paclitaxel	74	5.3	5.3
Epoetin Alfa	9	5.3	5.3
Capecitabine	68	5.3	5.3
Doxorubicin	66	5.2	5.2
Pertuzumab	19	4.9	4.9
Etoposide	50	4.8	4.8
Terbinafine Hydrochloride	6	4.7	4.7
Bortezomib	59	4.7	4.7
Nevirapine	6	4.6	4.6
Cyclophosphamide Injection, Solution	112	4.5	4.5
Cyclophosphamide	112	4.5	4.5
Cyclophosphamide For Injection	112	4.5	4.5
Bupivacaine	6	4.5	4.5
Erythropoietin	13	4.4	4.4
Mycophenilic Acid	13	4.4	4.4
Montelukast	52	4.4	4.4
Atezolizumab	24	4.3	4.3
Mesna Injection	5	4.2	4.2
Alteplase	9	4.2	4.2
Mesna	5	4.1	4.1
Dexamethasone 1.5 Mg	165	4.1	4.1
Pitavastatin Calcium	6	4.1	4.1
Dexamethasone	164	4.0	4.0
Busulfan	9	4.0	4.0
Docetaxel Anhydrous	38	4.0	4.0
Docetaxel	38	4.0	4.0
Hydroxyurea	12	4.0	4.0
Cytarabine	33	3.8	3.8
Aprepitant	10	3.8	3.8
Trastuzumab	36	3.7	3.7
Panitumumab	8	3.6	3.6
Dabigatran Etexilate	39	3.5	3.5
Dabigatran Etexilate Mesylate	34	3.3	3.3
Conjugated Estrogens And Medroxyprogesterone Acetate	11	3.2	3.2
Remdesivir	6	3.1	3.1
Gefitinib	4	3.1	3.1
Osimertinib	14	3.0	3.0
Polatuzumab Vedotin	4	2.9	2.9
Crizotinib	5	2.7	2.7
Nintedanib	12	2.7	2.7
Pembrolizumab	40	2.7	2.7
Abiraterone	5	2.6	2.6
Cetuximab	11	2.4	2.4
Asenapine Maleate	3	2.4	2.4
Bendamustine Hydrochloride	4	2.3	2.3
Dabrafenib	7	2.3	2.3
Trametinib	8	2.3	2.3
Medroxyprogesterone Acetate	16	2.2	2.2
Voxelotor	7	2.2	2.2
Daratumumab	12	2.1	2.1
Lenalidomide	117	2.0	2.0
Durvalumab	5	1.7	1.7
Sacubitril And Valsartan	25	1.5	1.5
Pomalidomide	19	1.3	1.3
Evolocumab	25	1.1	1.1
Levonorgestrel	31	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.